Melatonin

Alternative Medicine Review

Volumn 10, Issue 4, 2005, Pages 326-336

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

ANTIOXIDANT; MELATONIN; SEROTONIN; STARNOC; TEMAZEPAM; TRYPTOPHAN; ZALEPLON; ZOPICLONE;

AGING; BLOOD CLOTTING DISORDER; CANCER; CHRONOBIOLOGY; CIRCADIAN RHYTHM; DISORIENTATION; DIZZINESS; EPILEPSY; FATIGUE; HEADACHE; HORMONAL REGULATION; HORMONE METABOLISM; HUMAN; HUMAN CELL; IMMUNOMODULATION; JET LAG; LIGHT EXPOSURE; MAGNETIC FIELD; MENSTRUAL CYCLE; MIGRAINE; PINEAL BODY; REVIEW; SEIZURE; SHIFT WORKER; SIDE EFFECT; SLEEP DISORDER; METABOLISM;

MELATONIN;

EID: 29144525976     PISSN: 10895159     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (134)

1. Webb SM, Pulg-Domingo M. Role of melatonin in health and disease. Clin Endocrinol (Oxf) 1995;42:221-234.
2. Iuvone PM, Brown AD, Haque R, et al. Retinal melatonin production: role of proteasomal proteolysis in circadian and photic control of arylalkylamine N-acetyltransferase. Invest Ophthalmol Vis Sci 2002;43:564-572.
3. Conti A, Conconi S, Hertens E, et al. Evidence for melatonin synthesis in mouse and human bone marrow cells. J Pineal Rex 2000;28:193-202.
4. Aust S, Thalhammer T, Humpeler S, et al. The melatonin receptor subtype MT1 is expressed in human gallbladder epithelia. J Pineal Res 2004;36:43-48.
5. Lee PP, Pang SF. Melatonin and its receptors in the gastrointestinal tract. Biol Signals 1993;2:181-193.
6. Bergiannaki JD, Soldatos CR, Paparrigopoulos TJ, et al. Low and high melatonin secretors among healthy individuals. J Pineal Res 1995;18:159-164.
7. Haimov I, Laudon M, Zisapel N, et al. The relationship between urinary 6-sulphatoxymelatonin rhythm and insomnia in old age. Adv Pineal Res 1994;8:433-438.
8. Peirpaoli W, Regelson W. The Melatonin Miracle. New York, NY: Simon and Schuster; 1995:24-30.
9. Zeitzer JM, Daniels JE, Duffy JF, et al. Do plasma melatonin concentrations decline with age? Am J Med 1999;107:432-436.
10. Rousseau A, Petren S, Plannthin J, et al. Serum and cerebrospinal fluid concentrations of melatonin: a pilot study in healthy male volunteers. J Neural Transm 1999;106:883-888.
11. Vakkuri O. Diurnal rhythm of melatonin in human saliva. Acta Physiol Scand 1985;124:409-412.
12. Tan D, Manchester LC, Reiter RJ, et al. High physiological levels of melatonin in the bile of mammals. Life Sci 1999;65:2523-2529.
13. Morin D, Simon N, Depres-Brummer P, et al. Melatonin high-affinity binding to alpha-1-acid glycoprotein in human serum. Pharmacology 1997;54:271-275.
14. Pardridge WM, Mietus LJ. Transport of albuminbound melatonin through the blood-brain barrier. J Neurochem 1980;34:1761-1763.
15. Claustrat B, Brun J, Garry P, et al. A once-repeated study of nocturnal plasma melatonin patterns and sleep recordings in six normal young men. J Pineal Res 1986;3:301-310.
16. Waldhauser F, Waldhauser M, Lieberman HR, et al. Bioavailability of oral melatonin in humans. Neuroendocrinologv 1984;39:307-313.
17. DeMuro RL, Nafziger AN, Blask DE, et al. The absolute bioavailability of oral melatonin. J Clin Pharmacol 2000;40:781-784.
18. Di WL, Kadva A, Johnston A, Silman R. Variable bioavailability of oral melatonin. N Engl J Med 1997;336:1028-1029.
19. Aldhous M, Franey C, Wright J, Arendt J. Plasma concentrations of melatonin in man following oral absorption of different preparations. Br J Clin Pharmacol 1985;19:517-521.
20. Cajochen C, Krauchi K, von Arx MA, et al. Daytime melatonin administration enhances sleepiness and theta/alpha activity in the waking EEG. Neurosci Lett 1996;207:209-213.
21. Ferini-Strambi L, Zucconi M, Biella G, et al. Effect of melatonin on sleep microstructure: preliminary results in healthy subjects. Sleep 1993;16:744-747.
22. Wang F, Li J, Wu C, et al. The GABA(A) receptor mediates the hypnotic activity of melatonin in rats. Pharmacol Biochem Behav 2003;74:573-578.
23. Lewy AJ, Ahmed S, Jackson JM, Sack RL. Melatonin shifts human circadian rhythms according to a phase-response curve. Chronobiol Int 1992;9:380-392.
24. Deacon S, English J, Arendt J. Acute phase-shifting effects of melatonin associated with suppression of core body temperature in humans. Neurosci Lett 1994;178:32-34.
25. Cagnacci A, Krauchi K, Wirz-Justice A, Volpe A. Homeostatic versus circadian effects of melatonin on core body temperature in humans. J Biol Rhythms 1997;12:509-517.
26. Maestroni GJ. The immunotherapeutic potential of melatonin. Expert Opin Investig Drugs 2001;10:467-476.
27. Lissoni P, Ardizzoia A, Tisi E, et al. Amplification of eosinophilia by melatonin during the immunotherapy of cancer with interleukin-2. J Biol Regul Homeost Agents 1993;7:34-36.
28. Lissoni P, Barni S, Tancini G, et al. A study of the mechanisms involved in the immunostimulatory action of the pineal hormone in cancer patients. Oncology 1993;50:399-402.
29. Maestroni GJ, Conti A, Pierpaoli W. Role of the pineal gland in immunity. Circadian synthesis and release of melatonin modulates the antibody response and antagonizes the immunosuppressive effect of corticosterone. J Neuroimmunol 1986;13:19-30.
30. Cos S, Sanchez-Barcelo EJ. Differences between pulsatile or continuous exposure to melatonin on MCF-7 human breast cancer cell proliferation. Cancer Lett 1994;85:105-109.
31. Blask DE, Cos S, Hill SM, et al. Melatonin action and oncogenesis. In: Franchini F, Reiter RJ, eds. Role of Melatonin and Pineal Peptides in Neuroimmunomodulation. New York, NY: Plenum Press; 1991;233-240.
32. Banerjee S, Margulis L. Mitotic arrest by melatonin. Exp Cell Res 1973;78:314-318.
33. Blask DE, Sauer LA, Dauchy RT. Melatonin as a chronobiotic/anticancer agent: cellular, biochemical, and molecular mechanisms of action and their implications for circadian-based cancer therapy. Curr Top Med Chem 2002;2:113-132.
34. Reiter RJ, Tan DX, Qi WB. Suppression of oxygen toxicity by melatonin. Zhongguo Yao Li Xue Bao 1998;19:575-581.
35. Bromme HJ, Morke W, Peschke D, et al. Scavenging effect of melatonin on hydroxyl radicals generated by alloxan. J Pineal Res 2000;29:201-208.
36. Pieri C, Marra M, Moroni F, et al. Melatonin: a peroxyl radical scavenger more effective than vitamin E. Life Sci 1994;55:PL271-276.
37. Sewerynek E, Reiter RJ, Melchiorri D, et al. Oxidative damage in the liver induced by ischemia-reperfusion: protection by melatonin. Hepatogastroenterology 1996;43:898-905.
38. Noda Y, Mori A, Liburdy R, Packer L. Melatonin and its precursors scavenge nitric oxide. J Pineal Res 1999;27:159-163.
39. Antolin I, Rodriguez C, Sainz RM, et al. Neurohormone melatonin prevents cell damage: effect on gene expression for antioxidant enzymes. FASEB J 1996;10:882-890.
40. Barlow-Walden LR, Reiter RJ, Abe M, et al. Melatonin stimulates brain glutathione peroxidase activity. Neurochem Int 1995;26:497-502.
41. Montilla P, Tunez I, Munoz MC, et al. Antioxidative effect of melatonin in rat brain oxidative stress induced by Adriamycin. Rev Esp Fisiol 1997;53:301-305.
42. Gitto E, Tan DX, Reiter RJ, et al. Individual and synergistic antioxidative actions of melatonin: studies with vitamin E, vitamin C, glutathione and desferrioxamine (desferoxamine) in rat liver homogenates. J Pharm Pharmacol 2001;53:1393-1401.
43. Montilla P, Cruz A, Padillo FJ, et al. Melatonin versus vitamin E as protective treatment against oxidative stress after extra-hepatic bile duct ligation in rats. J Pineal. Res 2001;31:138-144.
44. Cagnacci A, Soldani R, Yen SS. Exogenous melatonin enhances luteinizing hormone levels of women in the follicular but not in the luteal menstrual phase. Fertil Steril 1995;63:996-999.
45. Cagnacci A, Soldani R, Yen SS. Melatonin enhances cortisol levels in aged but not young women. Eur J Endocrinol 1995;133:691-695.
46. Terzolo M, Revelli A, Guidetti D, et al. Evening administration of melatonin enhances the pulsatile secretion of prolactin but not of LH and TSH in normally cycling women. Clin Endocrinol (Oxf) 1993;39:185-191.
47. Voordouw BC, Euser R, Verdonk RE, et al. Melatonin and melatonin-progestin combinations alter pituitary-ovarian function in women and can inhibit ovulation. J Clin Endocrinol Metab 1992;74:108-117.
48. Cagnacci A, Arangino S, Renzi A, et al. Influence of melatonin administration on glucose tolerance and insulin sensitivity of postmenopausal women. Clin Endocrinol (Oxf) 2001;54:339-346.
49. Chiodera P, Volpi R, Capretti L, et al. Melatonin inhibits oxytocin response to insulin-induced hypoglycemia, but not to angiotensin II in normal men. J Neural Transm 1998;105:173-180.
50. Reiter RJ, Calvo JR, Karbownik M, et al. Melatonin and its relation to the immune system and inflammation. Ann N Y Acad Sci 2000;917:376-386.
51. Bilici D, Akpinar E, Kiziltunc A. Protective effect of melatonin in carrageenan-induced acute local inflammation. Pharmacol Res 2002;46:133-139.
52. Cabeza J, Alarcon-de-la-Lastra C, Jimenez D, et al. Melatonin modulates the effects of gastric injury in rats: role of prostaglandins and nitric oxide. Neurosignals 2003;12:71-77.
53. Siddiqui MA, Nazmi AS, Karim S, et al. Effect of melatonin and valproate in epilepsy and depression. Indian J Pharmacol 2001;33:378-381.
54. Sewerynek E. Melatonin and the cardiovascular system. Neuro Endocrinol Lett 2002;23:79-83.
55. Armstrong SM. Melatonin. The internal zeitgeber of mammals? Pineal Res Rev 1989;7:157-202.
56. Attenburrow ME, Dowling BA, Sharpley AL, Cowen PJ. Case-control study of evening melatonin concentration in primary insomnia. BMJ 1996;312:1263-1264.
57. MacFarlane JG, Cleghorn JM, Brown GM, Streiner DL. The effects of exogenous melatonin on the total sleep time and daytime alertness of chronic insomniacs: a preliminary study. Biol Psychiatry 1991;30:371-376.
58. Zhdanova IV, Wurtman RJ, Lynch HJ, et al. Sleep-inducing effects of low doses of melatonin ingested in the evening. Clin Pharmacol Ther 1995;57:552-558.
59. Dollins AB, Zhdanova IV, Wurtman RJ, et al. Effect of inducing nocturnal serum melatonin concentrations in daytime on sleep, mood, body temperature, and performance. Proc Natl Acad Sci U S A 1994;91:1824-1828.
60. Haimov I, Lavie P, Laudon M, et al. Melatonin replacement therapy of elderly insomniacs. Sleep 1995;18:598-603.
61. Rajaratnam SM, Middleton B, Stone BM, et al. Melatonin advances the circadian timing of EEG sleep and directly facilitates sleep without altering its duration in extended sleep opportunities in humans. J Physiol 2004;561:339-351.
62. Pinto LR Jr, Seabra Mde L, Tufik S. Different criteria of sleep latency and the effect of melatonin on sleep consolidation. Sleep 2004;27:1089-1092.
63. Dahlitz M, Alvarez B, Vignau J, et al. Delayed sleep phase syndrome response to melatonin. Lancet 1991;337:1121-1124.
64. Oldani A, Ferini-Strambi L, Zucconi M, et al. Melatonin and delayed sleep phase syndrome: ambulatory polygraphic evaluation. Neuroreport 1994;6:132-134.
65. Tzischinsky O, Lavie P. Melatonin possesses time-dependent hypnotic effects. Sleep 1994;17:638-645.
66. Paul MA, Gray G, MacLellan M, Pigeau RA. Sleep-inducing pharmaceuticals: a comparison of melatonin, zaleplon, zopiclone, and temazepam. Aviat Space Environ Med 2004;75:512-519.
67. Paul MA, Gray G, Kenny G, Pigeau RA. Impact of melatonin, zaleplon, zopiclone, and temazepam on psychomotor performance. Aviat Space Environ Med 2003;74:1263-1270.
68. Claustrat B, Brun J, David M, et al. Melatonin and jet lag: confirmatory result using a simplified protocol. Biol Psychiatry 1992;32:705-711.
69. Herxheimer A, Petrie KJ. Melatonin for the prevention and treatment of jet lag. Cochrane Database Syst Rev 2002;2:CD001520.
70. Folkard S, Arendt J, Clark M. Can melatonin improve shift workers' tolerance of the night shift? Some preliminary findings. Chronobiol Int 1993;10:315-320.
71. Sharkey KM, Fogg LF, Eastman CI. Effects of melatonin administration on daytime sleep after simulated night shift work. J Sleep Res 2001;10:181-192.
72. Pillar G, Shahar E, Peled N, et al. Melatonin improves sleep-wake patterns in psychomotor retarded children. Pediatr Neurol 2000;23:225-228.
73. Hayashi E. Effect of melatonin on sleep-wake rhythm: the sleep diary of an autistic male. Psychiatry Clin Neurosci 2000;54:383-384.
74. Tjon Pian Gi CV, Broeren JP, Starreveld JS, Versteegh FG. Melatonin for treatment of sleeping disorders in children with attention deficit/hyperactivity disorder: a preliminary open label study. Eur J Pediatr 2003;162:554-555.
75. Dolberg OT, Hirschmann S, Grunhaus L. Melatonin for the treatment of sleep disturbances in major depressive disorder. Am J Psychiatry 1998;155:1119-1121.
76. Lockley SW, Skene DJ, James K, et al. Melatonin administration can entrain the free-running circadian system of blind subjects. J Endocrinol 2000;164:R1-R6.
77. Singer CM, Moffit MT, Colling ED, et al. Low dose melatonin administration and nocturnal activity levels in patients with Alzheimer's disease. Sleep Res 1997;26:752.
78. Shamir E, Laudon M, Barak Y, et al. Melatonin improves sleep quality of patients with chronic schizophrenia. J Clin Psychiatry 2000;61:373-377.
79. Leppamaki S, Partonen T, Vakkuri O, et al. Effect of controlled-release melatonin on sleep quality, mood, and quality of life in subjects with seasonal or weather-associated changes in mood and behaviour. Eur Neuropsychopharmacol 2003;13:137-145.
80. Phillips L, Appleton RE. Systematic review of melatonin treatment in children with neurodevelopmental disabilities and sleep impairment. Dev Med Child Neurol 2004;46:771-775.
81. Lissoni P, Barni S, Meregalli S, et al. Modulation of cancer endocrine therapy by melatonin: a phase 11 study of tamoxifen plus melatonin in metastatic breast cancer patients progressing under tamoxifen alone. Br J Cancer 1995;71:854-856.
82. Lissoni P, Barni S, Ardizzoia A, et al. Randomized study with the pineal hormone melatonin versus supportive care alone in advanced nonsmall cell lung cancer resistant to a first-line chemotherapy containing cisplatin. Oncology 1992;49:336-339.
83. Neri B, Fiorelli C, Moroni F, et al. Modulation of human lymphoblastoid Interferon activity by melatonin in metastatic renal cell carcinoma. A phase 11 study. Cancer 1994;73:3015-3019.
84. Aldeghi R, Lissoni P, Barni S, et al. Low-dose interleukin-2 subcutaneous immunotherapy in association with the pineal hormone melatonin as a first-line therapy in locally advanced or metastatic hepatocellular carcinoma. Eur J Cancer 1994;30A:167-170.
85. Lissoni P, Barni S, Ardizzoia A, et al. A randomized study with the pineal hormone melatonin versus supportive care alone in patients with brain metastases due to solid neoplasms. Cancer 1994;73:699-701.
86. Lissoni P. Modulation of anticancer cytokines IL-2 and IL-12 by melatonin and other pineal indoles 5-methoxytryptamine and 5-methoxytryptophol in the treatment of human neoplasms. Ann N Y Acad Sci 2000;917:560-567.
87. Barni S, Lissoni P, Cazzaniga M, et al. A randomized study of low-dose subcutaneous interleukin-2 plus melatonin versus supportive care alone in metastatic colorectal cancer patients progressing under 5-fluorouracil and folates. Oncology 1995;52:243-245.
88. Lissoni P, Brivio F, Brivio O, et al. Immune effects of preoperative immunotherapy with high-dose subcutaneous interleukin-2 versus neuroimmunotherapy with low-dose interleukin-2 plus the neurohormone melatonin in gastrointestinal tract tumor patients. J Biol Regul Homeost Agents 1995;9:31-33.
89. Lissoni P, Barni S, Ardizzoia A, et al. Immunotherapy with low-dose subcutaneous interleukin-2 in association with melatonin as salvage therapy for metastatic soft tissue sarcomas. Oncol Rep 1997;4:157-159.
90. Mills E, Wu P, Seely D, Guyatt G. Melatonin in the treatment of cancer: a systematic review of randomized controlled trials and meta-analysis. J Pineal Res 2005;39:360-366.
91. Lissoni P, Bucovec R, Bonfanti A, et al. Thrombopoietic properties of 5-methoxytryptamine plus melatonin versus melatonin alone in the treatment of cancer-related thrombocytopenia. J Pineal Res 2001;30:123-126.
92. Barni S, Lissoni P, Paolorossi F, et al. Prevention of chemotherapy-induced thrombocytopenia by the pineal hormone melatonin (MLT). Proc Annu Meet Am Soc Clin Oncol 1996;15:528.
93. Lissoni P, Barni S, Brivio F, et al. Treatment of cancer-related thrombocytopenia by low-dose subcutaneous interleukin-2 plus the pineal hormone melatonin: a biological phase II study. J Biol Regul Homeost Agents 1995;9:52-54.
94. Lissoni P, Paolorossi F, Tancini G, et al. Is there a role for melatonin in the treatment of neoplastic cachexia? Eur J Cancer 1996;32A:1340-1343.
95. Lissoni P, Tancini G, Barni S, et al. Treatment of cancer chemotherapy-induced toxicity with the pineal hormone melatonin. Support Care Cancer 1997;5:126-129.
96. Cagnacci A, Arangino S, Angiolucci M, et al. Influences of melatonin administration on the circulation of women. Am J Physiol 1998;274: R335-R338.
97. Cagnacci A, Arangino S, Angiolucci M, et al. Potentially beneficial cardiovascular effects of melatonin administration in women. J Pineal Res 1997;22:16-19.
98. Cagnacci A, Arangino S, Angiolucci M, et al. Effect of exogenous melatonin on vascular reactivity and nitric oxide in postmenopausal women: role of hormone replacement therapy. Clin Endocrinol (Oxf) 2001;54:261-266.
99. Nishiyama K, Yasue H, Moriyama Y, et al. Acute effects of melatonin administration on cardiovascular autonomic regulation in healthy men. Am Heart J 2001;141:E9.
100. Cavallo A, Daniels SR, Dolan LM, et al. Blood pressure response to melatonin in type I diabetes. Pediatric Diabetes 2004;5:26-31.
101. Wakatsuki A, Okatani Y, Ikenoue N, et al. Effects of short-term melatonin administration on lipoprotein metabolism in normolipidemic postmenopausal women. Maturitas 2001;38:171-177.
102. Sandyk R, Awerbuch GI. The relationship between melatonin secretion and serum cholesterol in patients with multiple sclerosis. Int J Neurosci 1994;76:81-86.
103. Jan JE, Connolly MB, Hamilton D, et al. Melatonin treatment of non-epileptic myoclonus in children. Dev Med Child Neurol 1999;41:255-259.
104. Molina-Carballo A, Munoz-Hoyos A, Reiter RJ, et al. Utility of high doses of melatonin as adjunctive anticonvulsant therapy in a child with severe myoclonic epilepsy: two years' experience. J Pineal Res 1997;23:97-105.
105. Peled N, Shorer Z, Peled E, Pillar G. Melatonin effect on seizures in children with severe neurologic deficit disorders. Epilepsia 2001;42:1208-1210.
106. Sheldon SH. Pro-convulsant effects of oral melatonin in neurologically disabled children. Lancet 1998;351:1254.
107. Gupta M, Gupta YK, Agarwal S, et al. Effects of add-on melatonin administration on antioxidant enzymes in children with epilepsy taking carbamazepine monotherapy: a randomized, double-blind, placebo-controlled trial. Epilepsia 2004;45:1636-1639.
108. Gupta M, Gupta YK, Agarwal S, et al. A randomized, double-blind, placebo controlled trial of melatonin add-on therapy in epileptic children on valproate monotherapy: effect on glutathione peroxidase and glutathione reductase enzymes. Br J Clin Pharmacol 2004;58:542-547.
109. Brun J, Claustrat B, Saddier P, Chazot G. Nocturnal melatonin excretion is decreased in patients with migraine without aura attacks associated with menses. Cephalalgia 1995;15:136-139.
110. Claustrat B, Loisy C, Brun J, et al. Nocturnal plasma melatonin levels in migraine: a preliminary report. Headache 1989;29:242-245.
111. Murialdo G, Fonzi S, Costelli P, et al. Urinary melatonin excretion throughout the ovarian cycle in menstrually related migraine. Cephalalgia 1994;14:205-209.
112. Claustrat B, Brun J, Geoffriau M, et al. Nocturnal plasma melatonin profile and melatonin kinetics during infusion in status migrainosus. Cephalalgia 1997;17:511-517.
113. Nagtegaal JE, Smits MG, Swart AC, et al. Melatonin-responsive headache in delayed sleep phase syndrome: preliminary observations. Headache 1998;38:303-307.
114. Peres M, Zukerman E, da Cunha Tanuri F, et al. Melatonin, 3 mg, is effective for migraine prevention. Neurology 2004;63:757.
115. Naguib M, Samarkandi AH. Premedication with melatonin: a double-blind, placebo-controlled comparison with midazolam. Br J Anaesth 1999;82:875-880.
116. Naguib M, Samarkandi AH. The comparative dose-response effects of melatonin and midazolam for premedication of adult patients: a doubleblind, placebo-controlled study. Anesth Analg 2000;91:473-479.
117. Bangha E, Elsner P, Kistler GS. Suppression of UV-induced erythema by topical treatment with melatonin (N-acetyl-5-methoxytryptamine). A dose response study. Arch Dermatol Res 1996;288:522-526.
118. Fischer T, Bangha E, Elsner P, Kistler GS. Suppression of UV-induced erythema by topical treatment with melatonin. Influence of the application time point. Biol Signals Recept 1999;8:132-135.
119. Samples JR, Krause G, Lewy AJ. Effect of melatonin on intraocular pressure. Curr Eye Res 1988;7:649-653.
120. Garfinkel D, Zisapel N, Wainstein J, Laudon M. Facilitation of benzodiazepine discontinuation by melatonin: a new clinical approach. Arch Intern Med 1999;159:2456-2460.
121. Cardinali DP, Gvozdenovich E, Kaplan MR, et al. A double blind-placebo controlled study on melatonin efficacy to reduce anxiolytic benzodiazepine use in the elderly. Neuro Endocrinol Lett 2002;23:55-60.
122. Yeleswaram K, Vachharajani N, Santone K. Involvement of cytochrome p-450 isozymes in melatonin metabolism and clinical implications. J Pineal Res 1999;26:190-191.
123. von Bahr C, Ursing C, Yasui N, et al. Fluvoxamine but not citalopram increases serum melatonin in healthy subjects - an indication that cytochrome p450 CYP1 A2 and CYP2C19 hydroxylate melatonin. Eur J Clin Pharmacol 2000;56:123-127.
124. Ulbricht CE, Basch EM. Natural Standard Herb and Supplement Reference. St. Louis, MO: Elsevier Mosby, Inc.; 2005:519-520.
125. Ursing C, Wikner J, Brismar K, Rojdmark S. Caffeine raises the serum melatonin level in healthy subjects: an indication of melatonin metabolism by cytochrome p450(CYP)1 A2. J Endocrinol Invest 2003;26:403-406.
126. Wright KP Jr, Badia P, Myers BL, et al. Caffeine and light effects on nighttime melatonin and temperature levels in sleep-deprived humans. Brain Res 1997;747:78-84.
127. Murphy PJ, Myers BL, Badia P. Nonsteroidal anti-inflammatory drugs alter body temperature and suppress melatonin in humans. Physiol Behav 1996;59:133-139.
128. U.S. Food and Drug Administration. Special Nutritionals Adverse Events Monitoring System: registered case reports.
129. Stoschitzky K, Sakotnik A, Lercher P, et al. Influence of beta-blockers on melatonin release. Eur J din Pharmacol 1999;55:111-115.
130. Guardiola-Lemaitre B. Toxicology of melatonin. J Biol Rhythms 1997;12:697-706.
131. Dericks-Tan JS, Schwinn P, Hildt C. Dose-dependent stimulation of melatonin secretion after administration of Agnus castus. Exp Clin Endocrinol Diabetes 2003;111:44-46.
132. Burch JB, Reif JS, Noonan CW, et al. Melatonin metabolite excretion among cellular telephone users. Im J Radial Biol 2002;78:1029-1036.
133. Karasek M, Lerchl A. Melatonin and magnetic fields. Neuro Endocrinol Lett 2002;23:S84-S87.
134. Lovely RH. Recent studies in the behavioral toxicology of ELF electric and magnetic fields. Prog Clin Biol Res 1988;257:327-347.